Reason for request
- Since it is impossible to identify responding patients a priori and in order not to deprive certain patients of the possible slight clinical benefit observed in the short term with medicinal products for the symptomatic treatment of Alzheimer’s disease, the actual benefit of REMINYL should be considered to be low.
- The Committee proposes that continuing treatment beyond one year should be decided after discussions with the carer and the patient if possible, following a multidisciplinary team meeting involving the treating doctor, geriatrician and neurologist or psychiatrist, taking into account the care network under which the patient is being treated, and on condition that efficacy has been maintained for one year.
Clinical Added Value
|no clinical added value||
The transparency Committee considers that REMINYL does not provide any improvement in actual benefit (IAB) in the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type. This opinion is based on the available clinical data on efficacy, which reveal an effect size that is at best modest, established over the short term and mainly on cognitive disorders, the risk of onset of adverse effects and drug interactions and on the lack of data demonstrating long-term therapeutic benefit.
- REMINYL 19-10-2011 avis CT-10676
- Annexe I - Efficacité Alzheimer 19-10-2011
- Annexe II - Données utilisation 20-10-2011
- Annexe III - Recherche documentaire HAS
- Rapport d'évaluation des médicaments Alzheimer 19-10-2011
- ALZHEIMER 19102011 SYNTHESE
- Fiche BUM – Place des médicaments du traitement symptomatique de la maladie d’Alzheimer